Head to Head Analysis: Sunshine Biopharma (NASDAQ:SBFM) versus Nexentis Technologies (NASDAQ:NXTS)

Nexentis Technologies (NASDAQ:NXTS) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Nexentis Technologies and Sunshine Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexentis Technologies	1	0	0	0	1.00
Sunshine Biopharma	1	1	1	0	2.00

Sunshine Biopharma has a consensus target price of $70.00, indicating a potential upside of 6,696.12%. Given Sunshine Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Nexentis Technologies.

Volatility and Risk

Nexentis Technologies has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Profitability

This table compares Nexentis Technologies and Sunshine Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexentis Technologies	N/A	-304.79%	-178.91%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

Insider & Institutional Ownership

61.2% of Nexentis Technologies shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 6.5% of Nexentis Technologies shares are held by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Nexentis Technologies and Sunshine Biopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexentis Technologies	$210,000.00	9.46	-$4.00 million	($96.07)	-0.01
Sunshine Biopharma	$36.31 million	0.11	-$5.97 million	($10.15)	-0.10

Nexentis Technologies has higher earnings, but lower revenue than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Nexentis Technologies, indicating that it is currently the more affordable of the two stocks.

About Nexentis Technologies

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

About Sunshine Biopharma

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.